statement
SIM0725 is intended for the treatment of autoimmune diseases.
A statement by 先聲藥業集團. Statements are as reported by the cited publishers — not verified by DecisionGateway.
擬用於治療自身免疫性疾病
Discussion
Related claims
SIM0725 was independently developed by the company.先聲藥業集團 · statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).先聲藥業集團 · statementSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團 · investigationThe Ministry of Health is taking action.guzelolalim · statementThe directive introduces a quarterly review of medicine needs.Директиву № 1149/2026 · statementCagriSema is a fixed-dose combination formulation.界面新闻 · statement
More claims by 先聲藥業集團
SIM0725 was independently developed by the company.statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).statementSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.investigation
All claims by 先聲藥業集團